Gland Pharma reports 56 percent decline in Q4 profit on soft demand

Gland Pharma said it had a one-off expense of 564.6 million rupees as a provision for credit impaired financial assets related to a customer which filed for bankruptcy in the U.S. court. Accounting for this, the company's net profit came in at 786.8 million rupees.

Its earnings before interest, taxes, depreciation, and amortisation (EBITDA) margin contracted to 21% from 32% a year earlier.

Revenue from operations fell about 29% to 7.85 billion rupees, dragged by weak sales in domestic and international markets as well as production line shut down at a facility in Hyderabad.

Hyderabad-based Gland Pharma, which primarily operates under a business-to-business (B2B) model, generally derives 70% of its revenue from core markets that include the United States, Europe, Canada, Australia and New Zealand.

Its revenue from core markets dropped 23% from a year earlier.

The company operated in a "challenging business environment (in the year ended March)," Gland Pharma CEO Srinivas Sadu said in a statement.

Shares of the company closed 0.5% lower at 1331.95 rupees ahead of its results. The stock had declined about 20% in the March quarter, compared with a 5% decline in the Nifty Pharma index.

Majority stakeholder Fosun Pharma withdrew plans to sell its stake in Gland Pharma, local media ET Now reported last month, citing sources.

Read also: Fosun Pharma withdraws plans to sell stake in Gland Pharma